Profile data is unavailable for this security.
About the company
ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. It also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
- Revenue in SEK (TTM)8.10m
- Net income in SEK-45.37m
- Incorporated2015
- Employees18.00
- LocationExpreS2ion Biotech Holding ABRonnowsgatan 8 CHELSINGBORG 25225SwedenSWE
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cyxone AB | 0.00 | -22.16m | 12.56m | 3.00 | -- | 0.2684 | -- | -- | -0.1388 | -0.1388 | 0.00 | 0.1248 | 0.00 | -- | -- | 0.00 | -59.57 | -63.71 | -66.38 | -69.40 | -- | -- | -- | -- | -- | -- | 0.0157 | -- | -- | -- | 45.87 | -- | -13.31 | -- |
| XP Chemistries AB | 393.54k | -7.43m | 17.89m | 2.00 | -- | 0.5219 | -- | 45.46 | -0.2059 | -0.2059 | 0.0066 | 0.2357 | 0.0159 | 3.01 | 3.45 | 196,770.00 | -29.91 | -- | -31.74 | -- | -1,218.83 | -- | -1,887.54 | -- | 3.76 | -- | 0.00 | -- | -37.14 | -- | -1.55 | -- | -- | -- |
| Lipigon Pharmaceuticals AB | 9.33m | -20.25m | 24.03m | -- | -- | 0.9519 | -- | 2.58 | -0.3541 | -0.3541 | 0.1012 | 0.1702 | 0.2851 | -- | 0.7439 | -- | -61.91 | -314.67 | -76.67 | -426.49 | -- | -- | -217.15 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
| Ziccum AB | 5.56m | -23.18m | 37.82m | 10.00 | -- | 4.46 | -- | 6.81 | -1.63 | -1.63 | 0.3903 | 0.5312 | 0.2749 | -- | 3.31 | 694,500.00 | -114.67 | -68.51 | -163.12 | -76.47 | -- | -- | -417.19 | -2,598.03 | -- | -- | 0.0654 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
| StenoCare A/S | 4.90m | -26.36m | 40.90m | 9.00 | -- | 1.27 | -- | 8.34 | -1.04 | -1.04 | 0.1868 | 1.01 | 0.0948 | -- | 2.07 | -- | -50.98 | -28.16 | -68.69 | -35.47 | -- | -- | -537.63 | -371.06 | 0.6143 | -6.07 | 0.2763 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
| QUIA PHARMA AB (publ) | 2.36m | -13.86m | 41.72m | 8.00 | -- | 1.20 | -- | 17.68 | -2.02 | -2.02 | 0.0119 | 0.0233 | 0.0703 | -- | 21.36 | -- | -41.30 | -95.67 | -50.35 | -207.86 | 160.51 | 262.59 | -587.29 | -5,002.50 | -- | -46.79 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| Odi Pharma AB (publ) | 22.45m | 355.97k | 48.10m | -- | 135.10 | 21.69 | 134.00 | 2.14 | 0.0234 | 0.0234 | 1.47 | 0.1457 | 2.19 | 54.42 | 5.47 | -- | 3.48 | -35.08 | 14.86 | -44.27 | 2.07 | -- | 1.59 | -99.25 | 1.22 | 1.81 | -- | -- | 15,995.75 | -- | 105.16 | -- | -- | -- |
| Arctic Bioscience AS | 30.69m | -47.25m | 51.55m | 20.00 | -- | 0.2245 | -- | 1.68 | -1.91 | -1.91 | 1.24 | 9.27 | 0.1057 | 0.674 | 2.25 | 1,570,792.00 | -16.27 | -- | -18.44 | -- | 29.20 | -- | -153.95 | -- | 1.21 | -- | 0.0075 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 8.10m | -45.37m | 56.71m | 18.00 | -- | 0.629 | -- | 7.00 | -29.54 | -29.54 | 5.47 | 42.93 | 0.0772 | -- | 6.46 | 311,461.50 | -43.23 | -63.54 | -56.21 | -75.88 | -123.56 | -1.94 | -560.27 | -524.31 | -- | -- | 0.0065 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
| Elicera Therapeutics AB | 12.07m | -20.79m | 69.31m | 2.00 | -- | 2.68 | -- | 5.74 | -0.9137 | -0.9137 | 0.5059 | 0.7377 | 0.3224 | -- | 12.85 | 6,035,610.00 | -55.51 | -40.06 | -79.82 | -49.74 | -- | -- | -172.21 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| Oncozenge AB | 0.00 | -11.78m | 107.88m | -- | -- | 7.59 | -- | -- | -1.01 | -1.01 | 0.00 | 1.21 | 0.00 | -- | -- | -- | -55.08 | -- | -59.44 | -- | -- | -- | -- | -- | -- | -2,944.50 | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 30 Sep 2024 | 20.16k | 0.02% |
